Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Activation of direct and indirect pathways of glycogen synthesis by hepatic overexpression of protein targeting to glycogen
Robert M. O’Doherty, Per B. Jensen, Paul Anderson, John G. Jones, Hal K. Berman, Denise Kearney, Christopher B. Newgard
Robert M. O’Doherty, Per B. Jensen, Paul Anderson, John G. Jones, Hal K. Berman, Denise Kearney, Christopher B. Newgard
View: Text | PDF
Article

Activation of direct and indirect pathways of glycogen synthesis by hepatic overexpression of protein targeting to glycogen

  • Text
  • PDF
Abstract

Glycogen-targeting subunits of protein phosphatase-1, such as protein targeting to glycogen (PTG), direct the phosphatase to the glycogen particle, where it stimulates glycogenesis. We have investigated the metabolic impact of overexpressing PTG in liver of normal rats. After administration of PTG cDNA in a recombinant adenovirus, animals were fasted or allowed to continue feeding for 24 hours. Liver glycogen was nearly completely depleted in fasted control animals, whereas glycogen levels in fasted or fed PTG-overexpressing animals were 70% higher than in fed controls. Nevertheless, transgenic animals regulated plasma glucose, triglycerides, FFAs, ketones, and insulin normally in the fasted and fed states. Fasted PTG-overexpressing animals receiving an oral bolus of [U-13C]glucose exhibited a large increase in hepatic glycogen content and a 70% increase in incorporation of [13C]glucose into glycogen. However, incorporation of labeled glucose accounted for only a small portion of the glycogen synthesized in PTG-overexpressing animals, consistent with our earlier finding that PTG promotes glycogen synthesis from gluconeogenic precursors. We conclude that hepatic PTG overexpression activates both direct and indirect pathways of glycogen synthesis. Because of its ability to enhance glucose storage without affecting other metabolic indicators, the glycogen-targeting subunit may prove valuable in controlling blood glucose levels in diabetes.

Authors

Robert M. O’Doherty, Per B. Jensen, Paul Anderson, John G. Jones, Hal K. Berman, Denise Kearney, Christopher B. Newgard

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Expression of the mouse PTG transgene in liver, fasted/fed protocol. Ani...
Expression of the mouse PTG transgene in liver, fasted/fed protocol. Animals received either the AdCMV-βGAL or AdCMV-PTG adenoviruses. Ninety hours after viral administration, animals were either allowed to continue feeding ad libitum or were fasted for 24 hours. Multiplex RT-PCR was performed on liver RNA samples from these animals. Inspection of the data revealed that AdCMV-PTG–treated animals could be segregated into high-expresser (high) and low-expresser (low) groups. (a) Three representative samples for each group are displayed, showing amplification products for the mouse PTG transgene and the internal standard EF-1α. (b) Quantitative analysis of the ratio of PTG/EF-1α signals was performed on all samples by exposing gels to a phosphorimager screen, and processing the resulting scan with ImageQuant. Data represent the mean ± SEM for the following number of samples: fed PTG high expressers, n = 4; fed PTG low expressers, n = 8; fed βGAL controls, n = 6; fasted PTG high expressers, n = 5; fasted PTG low expressers, n = 3; fasted βGAL controls, n = 5. *Values were greater than in the βGAL control group (P < 0.001). #Values were greater in PTG high expressers than in PTG low expressers (P < 0.001).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts